Reports of drug-induced demyelination range from isolated monophasic events to multifocal disease fulfilling diagnostic criteria for multiple sclerosis (MS) and antibody mediated demyelinating disorders such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) associated disease (MOGAD) (3, 5, 8). This evidence concerns the gene MOG and myeloid sarcoma.